The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

NEW YORK, February 13, 2025--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...

Pfizer has pledged a whopping $1 billion upfront ... with drugs like CDK4/6 inhibitor Ibrance (palbociclib), PARP inhibitor Talzenna (talazoparib), hormonal therapy Aromasin (exemestane) and ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...